Man Group plc Makes New $552,000 Investment in MaxCyte, Inc. $MXCT

Man Group plc bought a new stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 448,958 shares of the company’s stock, valued at approximately $552,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Renaissance Technologies LLC raised its holdings in shares of MaxCyte by 153.3% during the first quarter. Renaissance Technologies LLC now owns 1,993,200 shares of the company’s stock worth $1,400,000 after acquiring an additional 1,206,300 shares in the last quarter. Vitruvian Partners LLP purchased a new position in MaxCyte in the second quarter valued at about $6,203,328. Brooklands Fund Management Ltd purchased a new position in MaxCyte in the first quarter valued at about $1,538,000. George Kaiser Family Foundation acquired a new position in MaxCyte in the 2nd quarter worth about $772,000. Finally, Capricorn Fund Managers Ltd purchased a new stake in shares of MaxCyte during the 1st quarter worth about $5,760,000. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

MaxCyte Price Performance

MaxCyte stock opened at $1.26 on Friday. The company has a market capitalization of $130.04 million, a price-to-earnings ratio of -3.82 and a beta of 1.52. MaxCyte, Inc. has a one year low of $0.64 and a one year high of $1.86. The company’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.02.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The company had revenue of $6.50 million during the quarter, compared to analysts’ expectations of $6.51 million. MaxCyte had a negative return on equity of 18.92% and a negative net margin of 114.77%. As a group, sell-side analysts anticipate that MaxCyte, Inc. will post -0.25 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. BTIG Research reaffirmed a “neutral” rating on shares of MaxCyte in a research report on Monday, August 24th. Finally, Weiss Ratings upgraded shares of MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 25th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MaxCyte has a consensus rating of “Hold” and a consensus price target of $5.00.

MaxCyte Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.